Benson Cheng

Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman.